First published

Long Term: West Pharmaceutical Services

Explore this signal

Long Term at a glance

Short reader summary

More complex injectable medicines could need higher-specification vial stoppers and delivery components, allowing a qualified supplier to capture repeat demand.

Exact asset or item

West Pharmaceutical Services

Asset type

Listed investment

Reference price

416.42

Currency code

USD

Price observed at

2026-11-13T16:00:00-05:00

What this number represents

Tracking price

What remains unproven

Historical tracking close, not a purchase or current executable entry. Product mix, customer concentration, fair value and future share appreciation remain unproven.

Exact asset or item

Exact asset or item

West Pharmaceutical Services

Asset type

Listed investment

Ticker

WST

Exchange

NYSE

How to identify this exact asset

NYSE: WST common listed equity; United States / USD. Source dossier: 15 November 2026, 16:55 SGT. Main time horizon: 2 years. CONDITIONAL OPPORTUNITY.

Price and what it means

Entry or reference price

416.42

Currency code

USD

Price observed at

2026-11-13T16:00:00-05:00

What this number represents

Tracking price

Price evidence status

Verified

Price source

8. WST historical closing price

Publisher: Stock Analysis

Original language: English

Reading access: partial

Underlying origin: WST-S8

published date precision: day

retrieved date precision: day

Source publication date 2026-11-13

Source retrieval date 2026-11-16

Matching price source ID

WST-S8

Purchase, sale and realised profit

Permanent original reference: USD 416.42 / Friday 13 November 2026, 16:00 EST / Stock Analysis historical closing-price page (URL as final source). This stays frozen for future corrections. Latest checked price: same 13 November historical close; no newer US session by this Sunday cutoff. Price change since original entry: 0.00 USD at this same reference observation only, NOT a trading gain; no new independent current executable price. Estimated result after costs: not assessable (zero executed shares; brokerage, spreads, FX and taxes are unknown). Actually sold: NO (no purchase was made). Forecast status: NOT YET DUE / UNRESOLVED. Next review: 15 May 2027; earlier trigger on next published company quarterly release. Preserve this baseline even if subsequent results contradict the thesis.

The developments we connected

Separate development

  1. What changed

    Q1 component growth

    Date of the development

    Evidence status

    Observed

    What the evidence shows

    Q1 revenue about USD 844.9 million with strong high-value product growth.

    Source IDs

    • WST-S3
  2. What changed

    Q2 component demand

    Date of the development

    Evidence status

    Observed

    What the evidence shows

    Q2 sales about USD 872.3 million, up about 13.8% as reported.

    Source IDs

    • WST-S2
  3. What changed

    Q3 component growth and division weakness

    Date of the development

    Evidence status

    Observed

    What the evidence shows

    Q3 sales about USD 874.5 million, up 8.7% reported; high-value components organic sales up 20.3%, while West Vantage declined 6.6% organically.

    Source IDs

    • WST-S1

Emerging insight

REPORT A (23 April: HVP sales accelerate) -> REPORT B (23 July: sustained products mix change) -> REPORT C (29 October: HVP demand still strong even as a different division weakens). Regulatory background from EU sterilisation rules adds a quality hurdle. Hidden link: after a sterile component is validated for a drug, switching providers can require costly re-qualification, which could aid repeat orders. This is a hypothesis about customer behaviour, not disclosed customer-specific contract pricing.

How this exact asset could benefit

Beneficiary: West through elastomer components, containment and device manufacturing. Proven: company-reported growth in higher-value components and cash-generation history. Not proven: all growth comes from GLP-1 drugs, regulation caused 2026 sales, market share increased, or the premium valuation will persist. Drug approval and a stopper sale are separate outcomes.

Who could benefit

  1. Who

    West Pharmaceutical Services

    How they could benefit

    Beneficiary: West through elastomer components, containment and device manufacturing. Proven: company-reported growth in higher-value components and cash-generation history. Not proven: all growth comes from GLP-1 drugs, regulation caused 2026 sales, market share increased, or the premium valuation will persist. Drug approval and a stopper sale are separate outcomes.

    Evidence status

    Still unproven

What we observed

23 April 2026, Pennsylvania: West reported Q1 revenue about USD 844.9 million with strong high-value product (HVP) growth. 23 July: Q2 sales about USD 872.3 million, up about 13.8% as reported. 29 October: Q3 sales about USD 874.5 million, up 8.7% reported, and high-value components organic sales up 20.3%, but the West Vantage division was down 6.6% on an organic basis. The European Commission maintains Annex 1 sterile-manufacturing guidance; most of the update took effect before 2026 and is not a new October 2026 regulation.

What remains unproven

Beneficiary: West through elastomer components, containment and device manufacturing. Proven: company-reported growth in higher-value components and cash-generation history. Not proven: all growth comes from GLP-1 drugs, regulation caused 2026 sales, market share increased, or the premium valuation will persist. Drug approval and a stopper sale are separate outcomes.

What to check before acting

Entry conditions

Read HVP organic-growth tables and quarterly cash flow; distinguish total revenue from division mix. Check customers concentration and regulatory disclosures. Do not assume one medicine can be linked to one WST component without product-level proof.

Possible upside

Upside: re-qualification friction preserves recurring high-margin component sales.

Possible downside

Downside: demand returns to lower-value parts and a high stock multiple contracts.

Price or return range method

Downside: demand returns to lower-value parts and a high stock multiple contracts. Base: premium products continue to take share of West revenue, with uneven segment growth. Upside: re-qualification friction preserves recurring high-margin component sales. Numerical future-price range: not estimated given uncertain product mix and drug/customer concentration. Publishing verification, 16 November 2026: historical close divided by FY2026 adjusted EPS guidance yields approximately 43.93–44.39 times, not a fair-value estimate. Numerical price targets are not supported by a verified terminal multiple or product/customer mix forecast.

Costs and fees

Spreads, broker/FX costs, exchange taxes where applicable and price gaps matter; no universal tax assumption.

How hard it may be to sell

NYSE trading is generally possible, but spreads, broker/FX costs, exchange taxes where applicable and price gaps matter; no universal tax assumption.

Key risks

Large drug companies may diversify suppliers or reduce orders after inventory stocking; process faults or recalls can be costly. Alternate explanation: a short-lived injectable-drug capacity boom. Disproof: HVP component organic sales growth under 5% for two successive quarters plus negative free cash flow across a subsequent year. NYSE trading is generally possible, but spreads, broker/FX costs, exchange taxes where applicable and price gaps matter; no universal tax assumption.

What an ordinary reader can do next

Read HVP organic-growth tables and quarterly cash flow; distinguish total revenue from division mix. Check customers concentration and regulatory disclosures. Do not assume one medicine can be linked to one WST component without product-level proof. Next quarterly West release date not confirmed. Compare HVP component sales with West Vantage and inspect whether Q3 inventory/seasonality reverses.

Original forecast record

Original forecast in full

Long Term: West Pharmaceutical Services

Category: Shares

Exact asset: NYSE: WST common listed equity

Country and currency: United States / USD

Published: 15 November 2026, 16:55 SGT

Information cutoff: 15 November 2026, 16:55 SGT

Main time horizon: 2 years

Current position: CONDITIONAL OPPORTUNITY

Publication clarification: 16 November 2026 (SGT). The 'Published' time in the source metadata above is the source dossier's issue time, not this website article's first-publication time. The live page records actual first publication separately.

The opportunity in one sentence

More complex injectable medicines could need higher-specification vial stoppers and delivery components, allowing a qualified supplier to capture repeat demand.

Entry price and date

Reference entry price: USD 416.42 per share; price observed Friday 13 November 2026 at 16:00 EST (Saturday 14 November 05:00 SGT), Stock Analysis history (underlying reported S&P Global Market Intelligence market data). Type of price: historical closing market quote, not broker order quote. Availability: listed common stock generally broker-accessible where legally allowed. Entry note: TRACKING PRICE ONLY, NOT AN ACTUAL PURCHASE.

What changed?

23 April 2026, Pennsylvania: West reported Q1 revenue about USD 844.9 million with strong high-value product (HVP) growth. 23 July: Q2 sales about USD 872.3 million, up about 13.8% as reported. 29 October: Q3 sales about USD 874.5 million, up 8.7% reported, and high-value components organic sales up 20.3%, but the West Vantage division was down 6.6% on an organic basis. The European Commission maintains Annex 1 sterile-manufacturing guidance; most of the update took effect before 2026 and is not a new October 2026 regulation.

Reported quarterly sales are not the same as cashQ1–Q3 2026 · US$ million; reported quarterly actuals
Horizontal scale 0 to 1000Ticks 0 · 250 · 500 · 750 · 1000
View chart values
Reported quarterly sales are not the same as cash
QuarterRevenue (US$ million)
Q1 2026844.9
Q2 2026872.3
Q3 2026874.5
Company-reported sales, rounded to one decimal as in the source dossier. Not free cash flow, profit or evidence that all growth came from GLP-1 drugs.

The connection most people may miss

REPORT A (23 April: HVP sales accelerate) -> REPORT B (23 July: sustained products mix change) -> REPORT C (29 October: HVP demand still strong even as a different division weakens). Regulatory background from EU sterilisation rules adds a quality hurdle. Hidden link: after a sterile component is validated for a drug, switching providers can require costly re-qualification, which could aid repeat orders. This is a hypothesis about customer behaviour, not disclosed customer-specific contract pricing.

Why validation could support repeat demand
  1. Validated sterile componentQualified for a particular drug or process
  2. Possible switching costChanging supplier may require requalification
  3. Potential repeat ordersOnly if customers retain the supplier
  4. Possible durable cashOnly after costs, investment and cash collection
OTR hypothesis, not disclosed customer-specific pricing, a measured switching-cost estimate or proof of future share appreciation.
Sources

How this could make money

Beneficiary: West through elastomer components, containment and device manufacturing. Proven: company-reported growth in higher-value components and cash-generation history. Not proven: all growth comes from GLP-1 drugs, regulation caused 2026 sales, market share increased, or the premium valuation will persist. Drug approval and a stopper sale are separate outcomes.

Why the entry price matters

USD 416.42 is a historical quote. Valuation needs sustainable free cash flow, capacity investments, organic HVP revenue excluding one-off stocking, R&D and capital needs. A high multiple leaves a long way to fall if premium-component growth normalises; no defendable entry discount is established.

Time-horizon forecast

Time-horizon forecast
Time-horizon forecast
HorizonReview dateWhat we expect or need to seeWhat would challenge it
6 months15 May 2027HVP growth and cash checks from two newer quartersHVP slows or operating cash weakens
1 year15 Nov 2027Full-year quality-component organic growth and FCFDivision weakness outweighs premium demand
2 years15 Nov 2028Repeat high-value mix growth, robust marginsInventory correction rather than durable demand
3 years15 Nov 2029Capacity earnings after maintenance capexCustomer losses or product failure
4 years15 Nov 2030Quality moat reflected in sustained cash per sharePrice concessions and commoditisation
5 years15 Nov 2031Long-run earnings track drug demand without boom pricingNot enough evidence yet
Original source forecast, 15 November 2026, 16:55 SGT. Review dates and wording retained; these are tests, not achieved outcomes.
Sources
  • OTR West Pharmaceutical source dossier · 15 November 2026, 16:55 SGT

Possible price outcomes

Downside: demand returns to lower-value parts and a high stock multiple contracts. Base: premium products continue to take share of West revenue, with uneven segment growth. Upside: re-qualification friction preserves recurring high-margin component sales. Numerical future-price range: not estimated given uncertain product mix and drug/customer concentration.

What could go wrong?

Large drug companies may diversify suppliers or reduce orders after inventory stocking; process faults or recalls can be costly. Alternate explanation: a short-lived injectable-drug capacity boom. Disproof: HVP component organic sales growth under 5% for two successive quarters plus negative free cash flow across a subsequent year. NYSE trading is generally possible, but spreads, broker/FX costs, exchange taxes where applicable and price gaps matter; no universal tax assumption.

What an ordinary person can do

Read HVP organic-growth tables and quarterly cash flow; distinguish total revenue from division mix. Check customers concentration and regulatory disclosures. Do not assume one medicine can be linked to one WST component without product-level proof.

What happens next?

Next quarterly West release date not confirmed. Compare HVP component sales with West Vantage and inspect whether Q3 inventory/seasonality reverses.

OTR tracking record

Permanent original reference: USD 416.42 / Friday 13 November 2026, 16:00 EST / Stock Analysis historical closing-price page (URL as final source). This stays frozen for future corrections. Latest checked price: same 13 November historical close; no newer US session by this Sunday cutoff. Price change since original entry: 0.00 USD at this same reference observation only, NOT a trading gain; no new independent current executable price. Estimated result after costs: not assessable (zero executed shares; brokerage, spreads, FX and taxes are unknown). Actually sold: NO (no purchase was made). Forecast status: NOT YET DUE / UNRESOLVED. Next review: 15 May 2027; earlier trigger on next published company quarterly release. Preserve this baseline even if subsequent results contradict the thesis.

Publishing verification

16 November 2026 (SGT). All eight original source links reopened successfully; the source dossier's earlier Q2 access limitation was not reproduced. Annex 1 generally applied from 25 August 2023, with point 8.123 applying from 25 August 2024. USD 416.42 remains the 13 November regular-session historical close, not an executable entry price. Entry price unavailable: no current executable quote was obtained. The separately observed USD 414.57 after-hours quote, dated 13 November 2026 at 19:53 EST (14 November 08:53 SGT), is not a replacement for the frozen reference. Issuer FY2026 adjusted EPS guidance of USD 9.38–9.48 implies a historical-price/forward-guidance ratio of approximately 43.93–44.39 times (416.42 divided by EPS). This is not fair value or a return forecast. No supported terminal multiple, product-mix or customer-concentration forecast establishes numerical multi-year price targets.

Original forecast date and time

2026-11-15T16:55:00+08:00

Forecasts and review dates

6 months

Review date

2027-05-15

Original forecast

HVP growth and cash checks from two newer quarters

What to measure

HVP growth and cash checks from two newer quarters

What must happen

HVP growth and cash checks from two newer quarters

What would challenge the forecast

HVP slows or operating cash weakens

Current outcome

Not yet due

1 year

Review date

2027-11-15

Original forecast

Full-year quality-component organic growth and FCF

What to measure

Full-year quality-component organic growth and FCF

What must happen

Full-year quality-component organic growth and FCF

What would challenge the forecast

Division weakness outweighs premium demand

Current outcome

Not yet due

2 years

Review date

2028-11-15

Original forecast

Repeat high-value mix growth, robust margins

What to measure

Repeat high-value mix growth, robust margins

What must happen

Repeat high-value mix growth, robust margins

What would challenge the forecast

Inventory correction rather than durable demand

Current outcome

Not yet due

3 years

Review date

2029-11-15

Original forecast

Capacity earnings after maintenance capex

What to measure

Capacity earnings after maintenance capex

What must happen

Capacity earnings after maintenance capex

What would challenge the forecast

Customer losses or product failure

Current outcome

Not yet due

4 years

Review date

2030-11-15

Original forecast

Quality moat reflected in sustained cash per share

What to measure

Quality moat reflected in sustained cash per share

What must happen

Quality moat reflected in sustained cash per share

What would challenge the forecast

Price concessions and commoditisation

Current outcome

Not yet due

5 years

Review date

2031-11-15

Original forecast

Long-run earnings track drug demand without boom pricing

What to measure

Long-run earnings track drug demand without boom pricing

What must happen

Long-run earnings track drug demand without boom pricing

What would challenge the forecast

Not enough evidence yet

Current outcome

Not yet due

Sources

Dated source

  1. Source ID

    WST-S1

    What this source supports

    Supports: HVP growth and West Vantage counter-evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

  2. Source ID

    WST-S2

    What this source supports

    Supports: Mid-year component demand. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: 403 on direct open; indexed excerpt checked.

  3. Source ID

    WST-S3

    What this source supports

    Supports: Earlier HVP evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

  4. Source ID

    WST-S4

    What this source supports

    Supports: Historical baseline and reporting methods. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

  5. Source ID

    WST-S5

    What this source supports

    Supports: Like-for-like previous-year comparison. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

  6. Source ID

    WST-S6

    What this source supports

    Supports: Existing quality regime, not newly enacted 2026. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

  7. Source ID

    WST-S7

    What this source supports

    Supports: Question/answer context and counter-evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Indexed secondary transcript; verify against issuer webcast.

  8. Source ID

    WST-S8

    What this source supports

    Supports: USD 416.42 close for frozen tracking. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

Source limits

Original source register

Each entry specifies the source and what it can establish. Retrieval checkpoint is a single edition-level check, not a claim to individual upstream HTTP completion clocks. Links are genuine direct URLs but some access remains partial.

1. Third-quarter 2026 results | West Pharmaceutical Services | source date: 29 Oct 2026 | US / English

https://www.investor.westpharma.com/news-releases/news-release-details/west-reports-third-quarter-2026-results

Supports: HVP growth and West Vantage counter-evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

2. Second-quarter 2026 results | West Pharmaceutical Services | source date: 23 Jul 2026 | US / English

https://www.investor.westpharma.com/news-releases/news-release-details/west-reports-second-quarter-2026-results

Supports: Mid-year component demand. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: 403 on direct open; indexed excerpt checked.

3. First-quarter 2026 results | West Pharmaceutical Services | source date: 23 Apr 2026 | US / English

https://www.investor.westpharma.com/news-releases/news-release-details/west-reports-first-quarter-2026-results

Supports: Earlier HVP evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

4. Fourth-quarter/full-year 2025 results | West Pharmaceutical Services | source date: 12 Feb 2026 | US / English

https://www.investor.westpharma.com/news-releases/news-release-details/west-reports-fourth-quarter-and-full-year-2025-results

Supports: Historical baseline and reporting methods. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

5. Third-quarter 2025 results | West Pharmaceutical Services | source date: 23 Oct 2025 | US / English

https://www.investor.westpharma.com/news-releases/news-release-details/west-reports-third-quarter-2025-results

Supports: Like-for-like previous-year comparison. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

6. EudraLex Volume 4 Annex 1 and sterile GMP | European Commission | source date: 2022 Annex 1 revision; implementation largely 25 Aug 2023, some provisions 2024 | EU / English

https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en

Supports: Existing quality regime, not newly enacted 2026. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

7. Q3 2026 earnings transcript | Stock Analysis | source date: Q3 2026, exact publication time not verified | US / English

https://stockanalysis.com/stocks/wst/transcripts/713957-q3-2026/

Supports: Question/answer context and counter-evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Indexed secondary transcript; verify against issuer webcast.

8. WST historical closing price | Stock Analysis / S&P Global Market Intelligence | source date: 13 Nov 2026 | US / English

https://stockanalysis.com/stocks/wst/history/

Supports: USD 416.42 close for frozen tracking. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.

Back to Signals